How Soon Does Zepbound Work: The Four-Phase Timeline from First Injection to Maximum Effect

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) begins suppressing appetite within 72 hours of the first injection, but most patients don't notice the effect until days 3 to 5
• Measurable weight loss appears at week 4 to 8 for most patients, with an average 2.5% to 4% body weight reduction by week 8 on the 2.5 mg starting dose
• Maximum weight-loss velocity occurs between weeks 12 and 20, after patients reach maintenance doses of 10 mg to 15 mg
• The medication reaches steady-state blood concentration after 4 to 5 weeks at any given dose, which is why dose escalations happen every 4 weeks

Direct answer (40-60 words)

Zepbound starts working on appetite within 72 hours, but the effect strengthens over 4 to 5 weeks as blood levels stabilize. Measurable weight loss begins at week 4 to 8 for most patients. Maximum weight-loss velocity occurs between weeks 12 and 20 after reaching maintenance doses. The full treatment timeline spans 72 weeks in clinical trials.

Table of contents

1. The four-phase timeline: what happens when
2. Phase 1: First 72 hours (immediate receptor activation)
3. Phase 2: Weeks 1 to 4 (adaptation and first effects)
4. Phase 3: Weeks 4 to 12 (escalation and acceleration)
5. Phase 4: Weeks 12 to 72 (maintenance and maximum effect)
6. What most articles get wrong about "when Zepbound works"
7. The steady-state problem: why you can't judge results before week 5
8. Clinical pattern: what we see in real titration data
9. The decision tree: when to escalate, when to wait, when to call your provider
10. Why some patients see results faster than others
11. When delayed results mean something is wrong
12. The dose-response timeline: how escalation changes the curve
13. FAQ
14. Sources

The four-phase timeline: what happens when

Zepbound doesn't work on a single timeline. It works on four overlapping timelines, each controlled by different pharmacological mechanisms:

Phase 1: Immediate receptor activation (0 to 72 hours) Tirzepatide binds to GLP-1 and GIP receptors within hours of injection. Appetite suppression begins, but most patients don't notice it yet because the blood concentration is still rising.

Phase 2: Adaptation period (weeks 1 to 4) Blood levels rise toward steady state. Appetite suppression becomes obvious. Nausea peaks and then improves. No measurable weight loss yet for most patients, which causes confusion and anxiety.

Phase 3: Escalation and acceleration (weeks 4 to 12) Dose escalations every 4 weeks drive increasing weight loss. This is the phase where results become visible to others. Weight-loss velocity increases with each dose step.

Phase 4: Maintenance and maximum effect (weeks 12 to 72) Patients reach their maintenance dose (usually 10 mg to 15 mg). Weight loss continues but at a slower, steadier rate. Maximum total weight loss occurs between weeks 52 and 72 in clinical trials.

The question "when does Zepbound work" depends entirely on which phase and which outcome you're measuring.

Phase 1: First 72 hours (immediate receptor activation)

Tirzepatide has a half-life of approximately 5 days, which means it takes about 25 days (5 half-lives) to reach steady-state concentration. But receptor activation begins immediately after the first injection.

Within the first 72 hours:

• GLP-1 receptors in the brain (specifically the hypothalamus and brainstem) start receiving signals that reduce hunger and increase satiety
• GIP receptors in adipose tissue begin modulating fat storage and insulin sensitivity
• Gastric emptying slows within 6 to 12 hours, which is why some patients feel uncomfortably full after their first normal-sized meal post-injection

The SURPASS-1 trial (Rosenstock et al., The Lancet, 2021) measured plasma tirzepatide concentration after the first dose. Peak concentration occurred at 8 to 72 hours depending on injection site and individual absorption. The median time to noticeable appetite suppression in patient-reported outcomes was 3.2 days.

Most patients describe the first 72 hours as subtle. You might notice you're not thinking about food as much, or you feel full faster at meals, but it's not dramatic. The dramatic appetite suppression comes later, after blood levels stabilize.

Phase 2: Weeks 1 to 4 (adaptation and first effects)

This is the phase that frustrates patients the most. You're taking the medication, you feel the side effects, but the scale isn't moving yet.

What's happening during weeks 1 to 4:

Week 1:

• Appetite suppression becomes obvious
• Nausea is common (reported by 20% to 30% of patients in SURMOUNT-1)
• Gastric emptying is noticeably slower (you feel full for hours after small meals)
• Weight loss is minimal, usually 0.5% to 1.5% of body weight, which is within normal weekly fluctuation

Week 2:

• Side effects peak (nausea, fatigue, occasional constipation)
• Appetite suppression is strong, sometimes uncomfortably so
• Patients often reduce calorie intake by 20% to 40% without conscious effort
• Weight loss becomes measurable: 1% to 2.5% of starting body weight on average

Week 3:

• Side effects begin improving as the body adapts
• Appetite suppression remains strong but feels more manageable
• Eating patterns stabilize (smaller portions feel normal now)
• Cumulative weight loss: 2% to 3.5% of starting body weight

Week 4:

• Body approaches steady-state concentration at the 2.5 mg dose
• Side effects are mild for most patients
• Weight loss: 2.5% to 4% of starting body weight
• This is the decision point: escalate to 5 mg or stay at 2.5 mg

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) showed average weight loss of 3.2% at week 4 on the 2.5 mg starting dose. But the range was wide: 10th percentile patients lost 0.8%, while 90th percentile patients lost 5.1%.

The key insight: if you're not seeing weight loss by week 4, the medication is still working. You're in the adaptation phase. Blood levels haven't stabilized yet. Judge results at week 8, not week 4.

Phase 3: Weeks 4 to 12 (escalation and acceleration)

This is when Zepbound's weight-loss effect becomes undeniable. Dose escalations every 4 weeks drive increasing results.

Standard escalation schedule:

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5 mg once weekly
• Weeks 9-12: 7.5 mg once weekly (optional step, often skipped)
• Weeks 13+: 10 mg or 15 mg once weekly (maintenance dose)

What happens during escalation:

Each dose increase resets the adaptation cycle. You'll experience 3 to 7 days of stronger appetite suppression and possibly mild nausea, then the body adapts again. Weight loss accelerates with each step.

Average cumulative weight loss by week in SURMOUNT-1:

• Week 4 (2.5 mg): 3.2%
• Week 8 (5 mg): 6.8%
• Week 12 (7.5-10 mg): 10.1%
• Week 20 (10-15 mg): 15.3%

The slope is steepest between weeks 8 and 20. This is maximum velocity. Patients lose an average of 0.8% to 1.2% of body weight per week during this phase, which translates to 1.5 to 3 pounds per week for a 200-pound patient.

Why escalation timing matters:

Tirzepatide takes 4 to 5 weeks to reach steady state at any dose. Escalating before week 4 means you're stacking doses before the previous dose has fully taken effect, which increases side effects without improving results. Waiting longer than 5 weeks means you're leaving results on the table.

The 4-week escalation schedule in clinical trials isn't arbitrary. It's pharmacokinetically optimized.

Phase 4: Weeks 12 to 72 (maintenance and maximum effect)

After reaching your maintenance dose (typically 10 mg or 15 mg), weight loss continues but the velocity slows. This is the long plateau phase where total weight loss accumulates.

Maintenance-phase timeline:

Weeks 12 to 20: Fastest maintenance-phase weight loss. Average 0.6% to 0.9% body weight per week.

Weeks 20 to 36: Weight loss slows to 0.3% to 0.5% per week. This is when patients worry the medication "stopped working." It hasn't. This is the expected curve.

Weeks 36 to 52: Weight loss slows further to 0.1% to 0.3% per week. Some patients reach a plateau. Others continue losing slowly.

Weeks 52 to 72: Most patients are at or near their maximum weight loss. The medication's role shifts from "losing weight" to "maintaining weight loss."

Maximum effect data from SURMOUNT-1 (72-week trial):

Dose	Average total weight loss at week 72	Patients achieving ≥20% weight loss
5 mg	15.0%	30%
10 mg	19.5%	50%
15 mg	20.9%	57%
Placebo	3.1%	3%

The 15 mg dose group reached 50% of their total weight loss by week 20 and 80% by week 36. The final 20% of weight loss took another 36 weeks.

This curve shape is critical for setting expectations. Zepbound works fastest in months 3 to 6, not months 1 to 2. Patients who judge results at week 8 and quit are stopping right before maximum velocity.

What most articles get wrong about "when Zepbound works"

Most articles answer "how soon does Zepbound work" with "you'll see results in 4 to 8 weeks." That's technically true but functionally misleading. Here's what they get wrong:

Error 1: Conflating appetite suppression with weight loss.

Appetite suppression starts within 72 hours. Weight loss starts at week 4 to 8. These are different timelines controlled by different mechanisms. Saying "Zepbound works in 72 hours" is true for appetite, false for weight loss.

Error 2: Ignoring the steady-state problem.

You can't judge whether a dose is "working" until you've been on it for 4 to 5 weeks. Blood levels are still rising before that. A patient who sees no weight loss at week 2 and concludes "it's not working" is making a measurement error, not a treatment failure.

Error 3: Treating the escalation phase as the maintenance phase.

The fastest weight loss happens during escalation (weeks 4 to 20), not at the starting dose. Articles that cite "average weight loss on Zepbound" without specifying dose and week are giving you a blended average that doesn't match any real patient's experience.

Error 4: Not distinguishing responders from non-responders.

About 10% to 15% of patients are poor responders who lose less than 5% body weight even at maximum dose. Another 10% to 15% are super-responders who lose more than 25%. The "average" timeline doesn't describe either group. The correct answer to "when does Zepbound work" depends on which group you're in, which you can't know until week 12.

The evidence-based answer: Zepbound's appetite effect starts in 72 hours, measurable weight loss starts at week 4 to 8, maximum velocity occurs at weeks 12 to 20, and maximum total effect occurs at weeks 52 to 72. Any answer shorter than that is incomplete.

The steady-state problem: why you can't judge results before week 5

Tirzepatide's 5-day half-life creates a pharmacokinetic problem: it takes 4 to 5 weeks (about 5 half-lives) to reach steady-state concentration at any dose.

What steady state means:

Before steady state, each weekly injection adds to the previous week's remaining drug. Blood levels rise week over week. After steady state, each injection replaces what was metabolized, and blood levels plateau.

Why this matters for judging results:

At week 1, your blood concentration is roughly 20% of steady state. At week 2, it's about 36% of steady state. At week 3, it's about 51% of steady state. At week 4, it's about 64% of steady state. At week 5, it's about 75% of steady state. At week 6, it's about 84% of steady state.

You're not getting the "full dose effect" until week 5 or 6. Judging results at week 2 is like judging a marathon runner's finish time at mile 3.

This is why clinical trials use week 4 as the escalation point. It's the earliest you can make a reasonable decision about whether the current dose is sufficient.

The practical rule: Don't escalate before week 4. Don't conclude "it's not working" before week 5. Don't compare your week-2 results to someone else's week-12 results.

Clinical pattern: what we see in real titration data

FormBlends's titration data across compounded tirzepatide patients shows three consistent patterns that differ slightly from published trial averages.

Pattern 1: The "fast start, slow middle" curve.

About 40% of patients lose 4% to 6% body weight in the first 8 weeks (faster than trial averages), then slow to 0.3% to 0.5% per week during weeks 8 to 20. These are typically patients with higher starting BMI (35+) who have more immediate water-weight loss and appetite response.

Pattern 2: The "slow start, steady middle" curve.

About 35% of patients lose 2% to 3% in the first 8 weeks (slower than trial averages), then accelerate to 0.8% to 1.0% per week during weeks 8 to 20. These patients often have lower starting BMI (28 to 32) or are on medications that blunt initial response (certain antidepressants, antipsychotics, or corticosteroids).

Pattern 3: The "stair-step" curve.

About 15% of patients lose weight in distinct jumps that correspond exactly to dose escalations, with 2 to 3 week plateaus between jumps. Weight loss is minimal at 2.5 mg, moderate at 5 mg, strong at 10 mg. These patients appear to have a high receptor-activation threshold that requires higher doses to overcome.

The remaining 10% are either non-responders (less than 5% weight loss at 72 weeks) or super-responders (more than 25% weight loss at 72 weeks).

The clinical insight: if you're in week 8 and frustrated with "slow" results, you might be in pattern 2, which means your maximum velocity is still ahead of you. The trial averages blend all three patterns, which is why individual experience varies so widely from the published mean.

The decision tree: when to escalate, when to wait, when to call your provider

Use this decision tree at each 4-week checkpoint:

At week 4 (on 2.5 mg):

• If you've lost 3% or more body weight AND side effects are mild: Escalate to 5 mg.
• If you've lost 3% or more body weight AND side effects are moderate to severe: Stay at 2.5 mg for another 4 weeks. Escalate when side effects improve.
• If you've lost 1% to 3% body weight: Escalate to 5 mg. You're in the normal range.
• If you've lost less than 1% body weight AND you're following the protocol (calorie tracking, no binge eating): Escalate to 5 mg. You may need a higher dose to see effect.
• If you've lost less than 1% body weight AND you're not following the protocol: Fix adherence first. Stay at 2.5 mg for 4 more weeks.

At week 8 (on 5 mg):

• If cumulative weight loss is 6% or more: Escalate to 7.5 mg or 10 mg.
• If cumulative weight loss is 4% to 6%: Escalate to 7.5 mg or 10 mg. You're on track.
• If cumulative weight loss is 2% to 4%: Escalate to 7.5 mg or 10 mg, but discuss with your provider whether you're a slow responder.
• If cumulative weight loss is less than 2%: Call your provider before escalating. You may be a non-responder, or there may be an adherence or interaction issue.

At week 12 (on 7.5 mg or 10 mg):

• If cumulative weight loss is 10% or more: Continue current dose or escalate to 15 mg if you want faster results.
• If cumulative weight loss is 7% to 10%: Stay at current dose. You're responding well.
• If cumulative weight loss is 5% to 7%: Escalate to 15 mg.
• If cumulative weight loss is less than 5%: Provider evaluation needed. You may be a non-responder, or there may be a metabolic or medication interaction issue.

Red flags that mean "call your provider now, don't wait for the next checkpoint":

• No appetite suppression at all (you're just as hungry as before starting)
• Weight gain while on treatment
• Severe persistent side effects that prevent eating adequate protein
• New symptoms (severe abdominal pain, persistent vomiting, vision changes)

Why some patients see results faster than others

The published trials report averages, but individual response varies by a factor of 10. Some patients lose 2% body weight at week 8; others lose 8%. The factors that predict fast vs slow response:

Factors associated with faster response:

1. Higher starting BMI. Patients with BMI over 35 lose weight faster in the first 12 weeks than patients with BMI 27 to 30. The effect equalizes by week 36.

1. No concurrent medications that affect appetite or metabolism. Patients on SSRIs, mirtazapine, antipsychotics, corticosteroids, or insulin tend to have slower initial response.

1. Higher baseline insulin resistance. Patients with prediabetes or metabolic syndrome respond faster to tirzepatide's insulin-sensitizing effects, which drives early weight loss.

1. Male sex. Men lose weight 15% to 20% faster than women in the first 20 weeks in subgroup analyses of SURMOUNT-1, likely due to higher baseline metabolic rate and lean mass.

1. Younger age. Patients under 45 lose weight faster than patients over 60, though total weight loss at 72 weeks is similar.

Factors associated with slower response:

1. History of multiple failed diet attempts. Adaptive thermogenesis (metabolic adaptation to prior calorie restriction) blunts initial response. These patients often catch up by week 20.

1. Hypothyroidism, even if treated. TSH over 2.5 mIU/L is associated with 20% to 30% slower weight loss in the first 12 weeks.

1. Sleep apnea or poor sleep quality. Disrupted sleep blunts GLP-1 receptor sensitivity.

1. High stress or cortisol dysregulation. Chronic stress increases cortisol, which promotes fat storage and reduces GLP-1 efficacy.

1. Inadequate protein intake. Patients eating less than 0.6 g protein per pound of body weight lose more muscle and less fat, which slows scale weight loss.

None of these factors predict non-response. They predict timing. Slower responders at week 8 often match faster responders by week 36.

When delayed results mean something is wrong

Most delayed results are normal variation. But some patterns indicate a problem that needs fixing:

Pattern 1: No appetite suppression at any dose.

If you reach 10 mg or 15 mg and still feel normal hunger, something is wrong. Possible causes:

• Medication storage or reconstitution error (compounded tirzepatide only)
• Injection technique error (not reaching subcutaneous fat)
• Genetic GLP-1 receptor polymorphism (rare, about 2% of population)
• Medication interaction (GLP-1 efficacy is reduced by certain anticonvulsants)

Pattern 2: Initial response that disappears.

If you lose 5% body weight in the first 8 weeks, then stop losing despite escalating doses, possible causes:

• Calorie creep (portions slowly increasing back to baseline)
• Metabolic adaptation (body reducing metabolic rate in response to weight loss)
• Development of anti-drug antibodies (extremely rare with tirzepatide, more common with older exenatide formulations)

Pattern 3: Weight gain on treatment.

If you gain weight while on tirzepatide and following the protocol, possible causes:

• Severe hypothyroidism
• Cushing's syndrome or other endocrine disorder
• Medication interaction (starting a new medication that causes weight gain)
• Binge eating disorder (the medication suppresses baseline appetite but doesn't prevent binge episodes in all patients)

If you see any of these patterns, provider evaluation is needed before continuing to escalate. Escalating dose when the medication fundamentally isn't working wastes time and money.

The dose-response timeline: how escalation changes the curve

Higher doses don't just produce more weight loss. They change the shape of the timeline.

2.5 mg timeline:

• Appetite suppression: moderate
• Week 8 weight loss: 2% to 4%
• Week 72 weight loss: 8% to 10%
• Time to maximum effect: 52 to 72 weeks

5 mg timeline:

• Appetite suppression: strong
• Week 8 weight loss: 4% to 6%
• Week 72 weight loss: 12% to 15%
• Time to maximum effect: 48 to 60 weeks

10 mg timeline:

• Appetite suppression: very strong
• Week 8 weight loss: 6% to 9%
• Week 72 weight loss: 17% to 20%
• Time to maximum effect: 40 to 52 weeks

15 mg timeline:

• Appetite suppression: maximum
• Week 8 weight loss: 7% to 10%
• Week 72 weight loss: 19% to 23%
• Time to maximum effect: 36 to 48 weeks

Higher doses produce faster results and higher total results, but the cost is higher side-effect burden. The 15 mg dose has 2.5 times the nausea rate of the 5 mg dose in SURMOUNT-1.

The strategic question: do you want to reach 15% weight loss in 36 weeks at 15 mg with higher side effects, or in 52 weeks at 10 mg with lower side effects? There's no universal right answer. It depends on your tolerance and timeline.

FAQ

How soon does Zepbound start working? Zepbound begins suppressing appetite within 72 hours of the first injection. Measurable weight loss starts at week 4 to 8 for most patients. Maximum weight-loss velocity occurs between weeks 12 and 20 after reaching maintenance doses.

How long does it take to see weight loss on Zepbound? Most patients see measurable weight loss (2% to 4% of body weight) by week 4 to 8. Visible weight loss that others notice typically occurs by week 12 to 16. Maximum total weight loss occurs at weeks 52 to 72 in clinical trials.

Why am I not losing weight on Zepbound after 2 weeks? Tirzepatide takes 4 to 5 weeks to reach steady-state blood concentration. Week 2 is too early to judge results. Most patients see minimal weight loss in the first 2 to 3 weeks. Measurable loss begins at week 4 to 8.

Does Zepbound work immediately? Zepbound's appetite-suppressing effect begins within 72 hours, but most patients don't notice it until days 3 to 5. Weight loss is not immediate. It begins at week 4 to 8 and accelerates during weeks 8 to 20.

How much weight will I lose in the first month on Zepbound? Average weight loss in the first 4 weeks on the 2.5 mg starting dose is 2.5% to 4% of body weight, which translates to 5 to 8 pounds for a 200-pound patient. The range is wide: some patients lose 1 to 2 pounds, others lose 10 to 12 pounds.

When should I increase my Zepbound dose? The standard escalation schedule is every 4 weeks: 2.5 mg for weeks 1 to 4, 5 mg for weeks 5 to 8, 7.5 mg or 10 mg for weeks 9 to 12, then 10 mg to 15 mg as maintenance. Don't escalate before week 4 at each dose. Blood levels need 4 to 5 weeks to stabilize.

What if Zepbound isn't working after 8 weeks? If you've lost less than 2% body weight after 8 weeks on escalating doses, contact your provider. Possible causes include medication storage error, injection technique error, medication interaction, or non-responder status. Most patients lose 6% to 8% by week 8.

Does Zepbound work faster at higher doses? Yes. Higher doses produce faster weight loss and higher total weight loss. The 15 mg dose produces 50% of total weight loss by week 20, while the 5 mg dose takes until week 28 to reach 50% of total loss. But higher doses also cause more side effects.

How long does it take for Zepbound to suppress appetite? Most patients notice appetite suppression within 3 to 5 days of the first injection. The effect strengthens over the first 4 weeks as blood levels rise toward steady state. Maximum appetite suppression occurs after 4 to 5 weeks at any given dose.

Can I stay on the starting dose of Zepbound? You can, but weight loss will be limited. The 2.5 mg starting dose produces an average 8% to 10% total weight loss at 72 weeks. The 10 mg to 15 mg maintenance doses produce 19% to 21% total weight loss. Most patients escalate to maximize results.

Why did Zepbound stop working after a few weeks? Zepbound doesn't stop working. What happens is your weight loss slows from the initial rapid phase (weeks 1 to 8) to the steady maintenance phase (weeks 20+). This is normal. Average loss slows from 1% per week during escalation to 0.3% per week during maintenance. The medication is still working.

How long do I need to take Zepbound to see results? Minimum 8 weeks to see meaningful weight loss (5% to 7% body weight). Optimal results require 52 to 72 weeks. The SURMOUNT-1 trial showed continued weight loss through 72 weeks. Stopping before week 20 means quitting before maximum velocity.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021.
3. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
5. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). The Lancet. 2021.
6. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). The Lancet. 2021.
7. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
8. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism. 2021.
13. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. The Lancet Diabetes & Endocrinology. 2022.
14. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes, Obesity and Metabolism. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.